Transgene operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Transgene with three other
pharmaceutical manufacturers in Europe:
of the United Kingdom
sales of £3.13 million [US$4.22 million]
of which 38%
Erytech Pharma SA
(3.36 million Euro [US$3.97 million]
of which 100%
was Pharmacy), and
Co Don AG
based in Germany
(5.96 million Euro [US$7.04 million]
During the year ended December of 2017, sales at
Transgene were 7.46 million Euro (US$8.80 million).
decrease of 14.6%
versus 2016, when the company's sales were 8.73 million Euro.
Contributing to the drop in overall sales was the 97.7% decline
in Research and Development Subsidies, from 129,000.00 Euro to 3,000.00 Euro.
There were also decreases in sales in
Research and Development Tax Credit (down 14.4% to 5.36 million Euro)
Royalties and Licenses (down 33.1% to 1.20 million Euro)
However, these declines were partially offset by the increase in sales of
Bio-Production and Cooperations (up 63.5% to 896,000.00 Euro)